Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N43CO120062
Agency Tracking Number: N43CO120062
Amount: $200,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2012
Solitcitation Year: 2012
Solitcitation Topic Code: NCI
Solitcitation Number: N/A
Small Business Information
2975 W. Executive Parkway, Suite 320, Lehi, UT, 84043
Duns: 969849004
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (801) 285-7570
Business Contact
Phone: (801) 285-7570
Research Institution
TP-0413 is a novel small molecule inhibitor of the BMP pathway that has significant potential to be developed to treat anemia of cancer. Anemia of cancer is cytokine driven and results in the up-regulation of a liver hormone called hepcidin through the function of BMP receptors. Increased hepcidin levels result in the storage of iron in cellular compartments resulting in low serum iron and anemia. Anemia of cancer is a significant health issue in a majority of cancer patients and is currently only treatableby blood transfusion. As an inhibitor of BMP signaling, TP-0413 has shown promise in cell-based and animal models. TP-0413 inhibits cytokine signaling and raises serum iron and red blood cells in mouse models of anemia. Ideally, TP-0413 will be developedas an oral agent and to this end, the studies described in this proposal aim at identifying and optimizing a pharmaceutical salt form of the compound that is orally available with enhanced efficacy. Furthermore, five-day repeat dose toxicity studies will be performed in rats in preparation for choosing a dose and schedule for GLP toxicity studies. The overarching goal of this work is to develop an optimized oral agent for the treatment of anemia in cancer.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government